Id: acc0168
Group: 1sens
Protein: H2AX
Gene Symbol: H2AX
Protein Id: P16104
Protein Name: H2AX_HUMAN
PTM: phosphorylation
Site: Ser139
Site Sequence: PSGGKKATQASQEY-------
Disease Category: Cancer
Disease: Leukemia
Disease Subtype: ALL
Disease Cellline:
Disease Info:
Drug: mitoxantrone
Drug Info: "Mitoxantrone is a synthetic anthracycline-derived antineoplastic agent that inhibits DNA and RNA synthesis by intercalating into DNA, inhibiting topoisomerase II, and disrupting cell cycle progression, primarily used in the treatment of malignant lymphoma, breast cancer, acute leukemia, and various solid tumors."
Effect: modulate
Effect Info: Protein phosphorylation increases after drug treatment.
Note: histone
Score: 3.0
Pubmed(PMID): 19411853
Sentence Index:
Sentence:

Sequence & Structure:

MSGRGKTGGKARAKAKSRSSRAGLQFPVGRVHRLLRKGHYAERVGAGAPVYLAAVLEYLTAEILELAGNAARDNKKTRIIPRHLQLAIRNDEELNKLLGGVTIAQGGVLPNIQAVLLPKKTSATVGPKAPSGGKKATQASQEY

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 139 U Acute myelogenous leukemia Phosphorylation 33691101
S 139 U Hepatocellular carcinoma Phosphorylation 25537504
S 139 U Multiple myeloma Phosphorylation 35190641

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: